FDA Approves Ribociclib with an Aromatase Inhibitor and Ribociclib and Letrozole Co-pack for Early High-Risk Breast Cancer By Ogkologos - October 28, 2024 708 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy of ribociclib with a non-steroidal aromatase inhibitor is based on the results from the NATALEE study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Patients With DCIS Reduce Risk Of Recurrence And Death If They... June 25, 2020 FDA Approves Brexucabtagene Autoleucel for Relapsed or Refractory B-Cell Precursor Acute... October 7, 2021 AI is impacting cancer care, but also the environment September 25, 2025 Study Estimates That 22% Of Breast Cancers Are Overdiagnosed And Won’t... January 30, 2020 Load more HOT NEWS What if we count all that still remains? FDA Grants Traditional Approval to Tarlatamab-dlle for Extensive Stage Small Cell... EMA Recommends Extension of Therapeutic Indications for Olaparib FDA Approves Asciminib for Philadelphia Chromosome-Positive Chronic Myeloid Leukaemia
